Today before the opening bell, International Stem Cell Corp.
announced that it has entered into the second phase of the existing Research
Agreement with Rohto Pharmaceutical Co., Ltd. (“Rohto”), a global Japanese
pharmaceutical company recognized as the second-largest consumer health company
in Japan.
Rohto acknowledged that ISCO’s human parthenogenetic neural
stem cells (hpNSCs) demonstrate consistent high quality and are suitable for
further use in Rohto’s research. This was determined after successfully
completing preliminary studies of ISCO’s proprietary cells. If Rohto
successfully validates hpNSCs’ efficacy in rodent models, which could lead to a
possible treatment of a variety of degenerative eye disorders, Rohto plans to
enter into negotiations of a definitive license agreement with ISCO in order to
license the company’s proprietary technology for therapeutic and commercial
use.
“Based on hpNSCs known performance in various animal models
we expect that in the next four months Rohto will be able to demonstrate the
efficacy of these stem cells in treating retinal degenerative disorders,”
stated Ruslan Semechkin, Ph.D., Chief Scientific Officer of ISCO.
For more information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment